Treatment pathways of lipid-lowering therapies in Germany 2016–2022
Clinical Research in Cardiology · 2026
DOI: 10.1007/s00392-025-02686-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Research in Cardiology, 2026. Verfasst von Julius L Katzmann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstraße 20, 04103, Leipzig, Germany. julius.katzmann@medizin.uni-leipzig.de. Hauptthemen laut MEDLINE: Cholesterol, LDL, Anticholesteremic Agents, PCSK9 Inhibitors, Cardiovascular Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daiichi-Sankyo, Universitätsklinikum Leipzig.
Abstract (Originalsprache)
Background
Despite the availability of effective LDL cholesterol (LDL-C)-lowering drugs, only a minority of patients achieves the guideline-recommended treatment targets. This analysis describes treatment pathways of lipid-lowering therapy (LLT) in Germany.
Methods
Health claims data were used to identify patients at high or very-high cardiovascular risk who received a LLT prescription 2016–2022. Treatment pathways and the time to switch or discontinue LLT were analysed for statins, ezetimibe, bempedoic acid (BA), and PCSK9 inhibitors (PCSK9i).
Results
Out of 3,487,827 insured persons, 247,529 met the inclusion criteria. The most frequent first-line LLT were statins in 96.3%. Ezetimibe, BA, and PCSK9i were first-line LLT in only 0.9%, 0.061%, and 0.046%, respectively. Only few patients experienced a change in their treatment regimen following LLT initiation. Prescriptions of BA and PCSK9i were mainly second-, third-, or fourth-line add-on treatment. Termination of treatment with BA and PCSK9i was less frequent compared to statins and ezetimibe. The median time to treatment discontinuation was 1.45, 1.04, 0.60, and 2.45 years for statins, ezetimibe, BA, and PCSK9i, respectively, and the median time to switch therapy was 4.81 and 4.87 years for ezetimibe and PCSK9i, respectively (median not reached for statins and BA).
Conclusions
Changes in LLT were only observed in a minority of patients. BA and PCSK9i were switched more frequently than statins and ezetimibe. BA was discontinued earlier, and PCSK9i later than the other agents. Continued efforts to maintain long-term adherence and overcome therapeutic inertia are needed to realise the potential of available LLT with proven cardiovascular benefit. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstraße 20, 04103, Leipzig, Germany. julius.katzmann@medizin.uni-leipzig.de.
- inav - privates Institut für angewandte Versorgungsforschung GmbH, Berlin, Germany.
- Gesundheitsforen Leipzig GmbH, Leipzig, Germany.
- Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstraße 20, 04103, Leipzig, Germany.
- Deutsches Arzneiprüfungsinstitut e. V. (DAPI), Berlin, Germany.
- Institut für Pharmazie, Freie Universität Berlin, Berlin, Germany.
Förderung
- Daiichi-Sankyo
- Universitätsklinikum Leipzig
Zitieren
APA
Katzmann, J. L., Grellmann, C., Leppert, B., Müller-Kozarez, I., Schulz, M., & Laufs, U. (2026). Treatment pathways of lipid-lowering therapies in Germany 2016–2022. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-025-02686-5
Vancouver
Katzmann JL, Grellmann C, Leppert B, Müller-Kozarez I, Schulz M, Laufs U. Treatment pathways of lipid-lowering therapies in Germany 2016–2022. Clinical Research in Cardiology. 2026. doi:10.1007/s00392-025-02686-5
BibTeX
@article{Katzmann2026,
author = {Katzmann, Julius L and Grellmann, Claudia and Leppert, Beate and Müller-Kozarez, Irina and Schulz, Martin and Laufs, Ulrich},
title = {Treatment pathways of lipid-lowering therapies in Germany 2016–2022},
journal = {Clinical Research in Cardiology},
year = {2026},
doi = {10.1007/s00392-025-02686-5}
}
EUVIMED